# Cannabinoids for Pediatric Medicine: Clinical Evidence Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/ > **Published:** 2026-03-18T21:20:01-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T09:36:11-04:00 > **Clinical Summary:** Explore cannabinoids pediatric clinical evidence with this review summarizing safety and efficacy data for medical use in children. --- Table of Contents - [Clinical Takeaway](#Clinical_Takeaway) - [#4 Cannabinoids for Medical Purposes in Children: A Living Systematic Review.](#4_Cannabinoids_for_Medical_Purposes_in_Children_A_Living_Systematic_Review) - [What This Study Teaches Us](#What_This_Study_Teaches_Us) - [Why This Matters Clinically](#Why_This_Matters_Clinically) - [Study Snapshot](#Study_Snapshot) - [Where This Paper Deserves Skepticism](#Where_This_Paper_Deserves_Skepticism) - [Dr. Caplan’s Take](#Dr_Caplan8217s_Take) - [Clinical Bottom Line](#Clinical_Bottom_Line) - [Related](#Related) #### Clinical Takeaway Cannabinoids have been studied across a wide range of pediatric medical conditions, with the current evidence base drawing from hundreds of studies including clinical trials and real-world observational data. The research reflects meaningful variability in study design, [cannabinoid formulations](https://cedclinic.com/brazil-cannabis-regulatory-framework-new-medical-rules/), and patient populations, making direct comparisons difficult. Safety and efficacy conclusions remain condition-specific, and clinical decisions should be guided by the strongest available evidence for each individual indication. ### #4 Cannabinoids for Medical Purposes in Children: A Living Systematic Review. **Citation:** Chhabra Manik et al. *Cannabinoids for Medical Purposes in Children: A Living [Systematic Review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/).* Acta paediatrica (Oslo, Norway: 1992). 2025. PMID: 40437694. **Study type:** Journal Article, Systematic Review, Research Support, Non-U.S. Gov’t  |  **Topic area:** Autism  |  **CED Score:** 13 Design: 5 Journal: 0 N: 2 Recency: 2 Pop: 3 Human: 1 Risk: 0 **Methodological Considerations:** - Small sample — underpowered for subgroup analysis **Abstract:** AIM: We developed a living systematic review (LSR) that will continuously map the safety and reported benefit data related to cannabinoid use for medical purposes in children. METHODS: MEDLINE, Embase, PsycInfo, and the Cochrane Library were searched from inception to April 2023. Studies involving at least one child  20% studies) in studies enrolling children were somnolence, diarrhoea, vomiting, and decreased appetite. CONCLUSION: These findings will continue to be updated to inform practice and reveal knowledge gaps for future research. ### What This Study Teaches Us A living systematic review of 276 studies found that purified CBD is the most commonly studied cannabinoid in children, showing a 30-50% reduction in seizure frequency in randomized trials for refractory epilepsy. Common adverse effects across pediatric studies include somnolence, diarrhea, vomiting, and decreased appetite, occurring in over 20% of studies. ### Why This Matters Clinically Clinicians are increasingly asked by families about cannabinoids for children with refractory epilepsy, cancer symptoms, and autism. This map of the current evidence base helps distinguish where we have actual trial data (seizures) versus observational reports (autism, cancer), and clarifies what side effects to counsel families about upfront. ### Study Snapshot **Study Design**Living systematic review (ongoing, updated continuously). Included 84 interventional, 131 observational, 54 survey, and 7 qualitative studies from inception through April 2023.**Population**Children under 18 years across 276 studies. Largest groups: refractory epilepsy (146 studies, 188,726 participants), cancer/cancer symptoms (30 studies, 208,753 participants), autism spectrum disorder (18 studies, 1,285 participants).**Intervention**Purified CBD (78.6% of interventional studies, 2-50 mg/kg/day), THC (6%, 2.5-10 mg/day), and nabilone (6%, 0.5-2 mg/day). Studies examined plant-derived or pharmaceutical cannabinoids.**Primary Outcome**Safety profile and reported benefit across medical indications. RCT subset assessed seizure reduction for epilepsy.**Key Result**In RCTs, purified CBD reduced seizure frequency by 30-50%. Somnolence, diarrhea, vomiting, and decreased appetite reported in over 20% of pediatric studies. ### Where This Paper Deserves Skepticism The abstract conflates interventional trials (most rigorous) with observational and survey data, making it hard to judge strength of evidence by indication. The huge participant numbers for cancer (208,753) and epilepsy (188,726) likely reflect database retrospectives or passive data collection rather than controlled trials, which waters down the apparent evidence. The abstract doesn’t specify how many of the 276 studies were actually RCTs versus observational, nor does it clarify whether the reported seizure reductions came from the same CBD formulation (Epidiolex) or heterogeneous preparations, which matters for clinical translation. ### Dr. Caplan’s Take I find this systematic review useful for what it does well: cataloging the landscape of cannabinoid research in children and flagging that most of the clinical work has been in refractory epilepsy. The 30-50% seizure reduction figure aligns with what we see in practice with purified CBD, though that reflects enriched RCT populations, not all children. What troubles me is the heterogeneity hidden in the numbers. Autism has 18 studies but only 1,285 total participants and no seizure endpoint to anchor on. Cancer symptom studies are even more scattered. The adverse event profile looks like what I counsel families about, but aggregating across indications and formulations obscures whether somnolence in an epilepsy child on polypharmacy is the same safety signal as in a cancer child. This is a helpful resource for point-of-care searching, not a substitute for critically reading the underlying trials. ### Clinical Bottom Line Purified CBD has the strongest evidence base for refractory epilepsy in children (30-50% seizure reduction in RCTs). For other indications like autism and cancer symptoms, evidence remains largely observational, and clinicians should counsel families that somnolence, GI upset, and appetite changes are common and should be monitored.  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40437694/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336964/)[DOI ↗](https://doi.org/10.1111/apa.70140) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoids for Pediatric Use: Clinical Evidence Review](https://cedclinic.com/cannabinoids-for-pediatric-use-evidence-review/) A comprehensive review of [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) on cannabinoid use in pediatric patients, focusing on safety and therapeutic outcomes. [Read More](https://cedclinic.com/cannabinoids-for-pediatric-use-evidence-review/) [Cannabinoids for Pediatric Medicine: Clinical Evidence Review](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) Detailed insights into clinical trials and observational studies assessing cannabinoids in pediatric medicine. [Explore Article](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) [Cannabinoids for Children: Clinical Evidence Reviewed](https://cedclinic.com/cannabinoids-pediatric-safety-evidence-review/) Review of safety and efficacy data for cannabinoids used in pediatric populations, highlighting key clinical findings. [Learn More](https://cedclinic.com/cannabinoids-pediatric-safety-evidence-review/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoids%20in%20Pediatric%20Medicine%3A%20Evidence-Based%20Care%20and%20Emerging%20Research&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-pediatric-clinical-evidence-review%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-pediatric-clinical-evidence-review%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoids%20in%20Pediatric%20Medicine%3A%20Evidence-Based%20Care%20and%20Emerging%20Research%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-pediatric-clinical-evidence-review%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).